- HATIP #119, October 2nd, 2008
- HATIP #117, September 9th, 2008
- HATIP #116, 5th September 2008
- HATIP #115, 14th August 2008
- HATIP #114, 24th July 2008
- HATIP #112, 26th June 2008
- HATIP #111, 19th June 2008
- HATIP #109, 29th May 2008
- HATIP #108 part 1, 16th May 2008
- HATIP #108, part 2, 16th May 2008
- HATIP #107, 30th April 2008
- HATIP #106, 17th April 2008
- HATIP #105, 31st March 2008
- HATIP #104, 31st March 2008
- HATIP #103, 12th March 2008
- HATIP #102, 28th February 2008
- HATIP #101, 14th February 2008
- HATIP #100, 31st January 2008
- HATIP #99, 17th January 2008
HATIP #103, 12th March 2008
Five years of HIV & AIDS Treatment in Practice

We began publishing HIV & AIDS Treatment in Practice five years ago this week. The original stated aim of the newsletter was to reflect the evolving practice of HIV treatment in resource-limited settings at a time when many physicians were just getting to grips with the possibility of providing antiretroviral therapy.
Within six months the World Health Organization had declared a global health emergency and issued guidelines recommending the use of fixed dose combination ARVs in resource-limited settings. WHO also set an ambitious target of 3 million on treatment by the end of 2005 – 3x5 – that catalysed activity worldwide.
Since then, numbers on treatment have expanded – but the 3x5 target wasn’t reached. By December 2006 only 2.1 million people in developing countries were receiving treatment, even though the leaders of the world’s wealthiest nations had agreed in 2005 that universal access to HIV treatment, prevention and care by 2010 should be the aim of the global community, a commitment reaffirmed by a UN General Assmebly Special Session in June 2006.
Since 2003 HATIP has covered a wide range of subjects, but we keep coming back to a number of areas as practice continues to evolve (follow links to an index of articles on each subject):
- Prevention of mother to child transmission: since 2003 the messages have become increasingly complex, and it’s become clear that the operational implementation of new findings is challenging. There’s still a big need to share best practice in this area.
- Retention in care: Now that people are in care, what do we do to retain them and keep them on treatment — hopefully to live into old age? Bringing treatment as close to where they live as possible, addressing their needs holistically and supporting their care through community-based mechanisms will be crucial. We expect to keep reporting on best practices that keep people living with HIV in care for some time to come.
- Treatment failure: how to define it, how to spot it and what to do about it remains controversial.
- Palliative care: pain relief, symptom management and quality of life remain neglected or poorly supported. Our series of clinical reviews, supported by the Diana, Princess of Wales Memorial Fund, aims to incorporate palliative care into the basic package of care received by people with HIV – and to give community organisations the facts to advocate for it.
- Tuberculosis: integrating HIV and TB care is one of the great challenges faced today. HATIP has covered TB/HIV issues extensively over the past two years, and will continue to do so in collaboration with WHO’s Stop TB Networks and a growing network of experts in HIV and TB care.
Where HATIP readers are
HATIP has just under 29,000 subscribers in over 100 countries.
Around 45% of HATIP’s readership is in sub-Saharan Africa, and 61% of the total readership is in resource-limited settings. Although we cannot quantify it, we suspect from analysis of email addresses that a high proportion of the North American, UK and European readers are either directly involved in HIV care in resource-limited settings or working in research and policy roles.
Excluding the UK and the United States, the top 15 countries represented in HATIP’s readership are, in order of subscribers: South Africa (almost 10% of all subscribers), India, Kenya, Nigeria, Uganda, Zambia, Zimbabwe, Tanzania, Ethiopia, Brazil, Malawi, Thailand, Mozambique and Ghana.
The English-language bias of our readership is clear, which is why we are currently seeking funding for a francophone edition of HATIP.
We would also like to recruit more clinical advisers from India – if you are an experienced HIV physician with a large clinic population and able to provide comment and input on articles, we’d love to hear from you!
About HATIP
A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.
Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.
Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.
latest aidsmap news
- High rate of death amongst patients with HIV diagnosed late
- CD4 cell count increases sustained up to five years in developing-world treatment programmes
- Raltegravir may have role in PEP if exposure involves drug-resistant HIV
- Excellent outcomes from five years of antiretroviral use in Botswana
- Study explores verbal and non-verbal communication in unprotected sex between men
- IL-2 provides quick ‘AIDS rescue’, but effect does not always last
- Once-a-day etravirine should work as first-line treatment
- Second-line combinations fail twice as often as first-line ones in the first year
- If you can't switch, better to stay on failing treatment than stop it, studies show
- Non-nucleoside resistance is efficiently transmitted within infection ‘clusters’
